A Study of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (MK-1088-002)

Trial Identifier: 1088-002
Sponsor: MSD
Start Date: July 2022
Primary Completion Date: September 2023
Study Completion Date: September 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Results Plain Language Summary – English
Results Plain Language Summary – EMEA Danish
Results Plain Language Summary – NA French (Canadian)

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 2M9
Canada, QC Quebec, QC, Canada, G1J 1Z4
Denmark, Hovedstaden Copenhagen, Hovedstaden, Denmark, 2730
Denmark, Hovedstaden Copenhagen, Hovedstaden, Denmark, 2100
Denmark, Syddanmark Odense, Syddanmark, Denmark, 5000
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9112001
Switzerland, Grisons Chur, Grisons, Switzerland, 7000
Switzerland, Sankt Gallen st.Gallen, Sankt Gallen, Switzerland, 9007
Switzerland, Ticino Bellinzona, Ticino, Switzerland, 6500
United States, FL Miami, FL, United States, 33136
United States, NY New York, NY, United States, 10016
United States, TX San Antonio, TX, United States, 78229